Urbano Anido Herranz

8PUBLICATIONS
44CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Diagnostic radiography
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Oct 30, 2024
Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma.

Aude Fléchon, Rafael Morales-Barrera, Thomas Powles

|Sep 12, 2024
Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use of 177Lu-PSMA-617 radioligand-therapy in prostate cancer.

Ovidio Fernández Calvo, José Muñoz Iglesias, Estephany Abou Jokh Casas

|Oct 06, 2022
Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer.

Urbano Anido Herranz

|Jun 20, 2020
Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.

Thomas Powles, Mark Kockx, Alejo Rodriguez-Vida

|Nov 06, 2019
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.

Thomas Powles, Mark Kockx, Alejo Rodriguez-Vida

|Jul 28, 2018
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer.

U Anido-Herranz, N Fernández-Núñez, J Afonso-Afonso

Pageof 2

Frequent Collaborators

4 joint publications

Thomas Powles

3 joint publications

Aaron Prendergast

3 joint publications

Pieter-Jan van Dam

3 joint publications

Maria Jose Mendez